Navigation Links
Updated Overall Survival Data From Pivotal Herceptin Adjuvant,Studies in HER2-Positive Breast Cancer

monitis, which occurred at a rate of less than 1 percent.

An update of cardiac function in patients enrolled in the NSABP B-31 trial presented by Priya Rastogi, M.D., of the University of Pittsburgh Cancer Institute (Abstract #513 -- Monday, June 4, 2007, 9:15 a.m. CDT), showed that the five-year cumulative incidence of cardiac events in the Herceptin-containing treatment arm was 3.8 percent, compared to 0.9 percent in the control arm. The cumulative incidence of cardiac dysfunction in the Herceptin arm remained stable, with no increase in cardiac events between year three and year five of follow-up, providing important insights into the long-term cardiac effects of Herceptin.

About Herceptin

Herceptin is a targeted therapeutic antibody treatment for women who have tumors that overexpress the human epidermal growth factor receptor 2 (HER2) protein. HER2-positive breast cancer is an especially aggressive form of the disease that affects approximately one-fourth of women with breast cancer. Research has shown that women with HER2-positive breast cancer have a greater likelihood of recurrence, poorer prognosis, and decreased survival compared to women with HER2-negative breast cancer. Special testing is required to identify women who have HER2-positive breast cancer and who may be candidates for treatment with Herceptin.

Herceptin is the only targeted biologic therapy approved for treatment of HER2-positive breast cancer in the adjuvant and metastatic settings. Herceptin first received FDA approval in September 1998 for use in metastatic breast cancer, as a first-line therapy in combination with paclitaxel and as a single agent in second- and third-line therapy. In clinical trials of patients with HER2-positive metastatic breast cancer, Herceptin, in combination with chemotherapy (paclitaxel), was the first anti-HER2 agent to demonstrate an improvement in survival in a Phase III study. In December 2001, Genentech received FDA approval to inc
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
3. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
4. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
5. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
6. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
7. Media Advisory: ACC Updated Schedule
8. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
9. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
10. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
11. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
Post Your Comments:
(Date:5/16/2008)...ata from three studies,evaluating associations bet...d the rate of blood transfusions, as well as the p...r erythropoiesis-stimulating agents (ESAs),in Medi...e presented at the,American Society of Clinical On... meeting will take place in Chicago from May 30 to...
(Date:5/16/2008)...ion of a Small Molecule with Dem...., May 16 /- Nektar,Therape...oday from a Phase 1,study of NKTR- 102, PEGylated ...activity in patients with refractory solid tumors....olecule PEGylation technology,produced an increase...
(Date:5/16/2008)...r Novel Approach to Blood ...wire-FirstCall/ -- Pharmacopeia (Nasdaq:,PCOP), an...el small,molecule therapeutics, announced today th...or Antagonist (DARA), showed statistically signifi... in patients with mild to,moderate hypertension. P...
(Date:5/15/2008)...- Eisai Corporation of North,America announced tod...out,compounds in the company,s oncology pipeline, ...h have been accepted for presentation at the,44th ... Oncology (ASCO),taking place in Chicago from May... on Eisai marketed products and,investigational co...
Breaking Medicine Technology:New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Hospital Launches Landmark Project in Emergency Medicine 9268 1Hospital Launches Landmark Project in Emergency Medicine 9268 2Hanger Orthopedic Group Inc Announces 2007 Year End Earnings Release Conference Call 9265 1Hanger Orthopedic Group Inc Announces 2007 Year End Earnings Release Conference Call 9265 2International Association of Fire Fighters 28IAFF 29 Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO Oximetry 2508 1International Association of Fire Fighters 28IAFF 29 Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO Oximetry 2508 2International Association of Fire Fighters 28IAFF 29 Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO Oximetry 2508 3International Association of Fire Fighters 28IAFF 29 Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO Oximetry 2508 4International Association of Fire Fighters 28IAFF 29 Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO Oximetry 2508 5Other highlights in the Jan 8 JNCI 9262 1Other highlights in the Jan 8 JNCI 9262 2Other highlights in the Jan 8 JNCI 9262 3Other highlights in the Jan 8 JNCI 9262 4
...- CombinatoRx,Incorporated (NASDAQ: CRXX) today a...ed to its immuno-inflammatory product,candidates, ...t,Rheumatism (EULAR) Annual Congress of Rheumatolo... CRx-102 , In a poster entitled "Inhibition of Mac...CRx-102, a Novel Synergistic Combination,Drug Cand...
...bjective Sleep,Measures, MINNEAPOLIS, June 13, 200...ults presented today at SLEEP 2007, the 21st annua...ieties (APSS),VEC-162, a balanced melatonin (MT1/...rmaceuticals Inc. , demonstrated improvements,in o...d maintenance,in a Phase III trial of transient in...
Other Medicine Technology:Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 2Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 3Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 4Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and,Maintenance vs. Placebo 2Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and,Maintenance vs. Placebo 3Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and,Maintenance vs. Placebo 4
(Date:5/16/2008)...o Save Vital Services for Frail Seniors and People...wswire-USNewswire/ -- Thousands of,homecare worker...warzenegger,s proposed cuts to hours of service, w...ornia,s most vulnerable workers and the,people the...these vital,services for seniors and people with d...
(Date:5/16/2008)...sents Urban Health Institute with 10,000 Sensual O...rg at Playboy Mansion Fundraiser, LOS ANGELES, Ma...ip-hop,and R & B artist J Kwon known best for his ...ll be presenting the Urban Health Institute (UHI) ... over $50,000. The donation is,being made to promo...
(Date:5/16/2008)...docs determine who would benefit most from chemo a... 16 (HealthDay News) -- A panel of 15 genes may he...mall cell lung cancer will experience a recurrence...y, a new study shows. , By extension, the same... less aggressive forms of the cancer who would be ...
(Date:5/16/2008)...TON, May 16 /PRNewswire-USNewswire/ -- As tropical...e Irrawaddy delta, survivors of,Cyclone Nargis are... Many,survivors still need assistance, as exposure... an increasingly dire situation., "The people liv...,recover from this disaster and get back on their ...
Breaking Medicine News(10 mins):Health News:Homecare Workers Outraged by Proposed Cuts, Wage Reductions 2Health News:Everybody in the Club Scream O! 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3Health News:Myanmar Cyclone Survivors Face New Challenges 2
...dually increased recommendations for daily calcium...00 and 1,300 milligrams // to promote healthy bone... in a medical journal said boosting consumption of... the best way to provide the minimal calcium intak...
...ering from the most common form of brain cancer mi... and // chemotherapy than radiotherapy alone . Bas...people with the type of cancer known as glioblasto...the cancer as safely possible and then undergo rad...
... the opinion that dairy products provide the neces...n a study conducted recently on collected informat...hildren and adolescence and consumption of dairy p...p between the two. Children are often advised to t...
...ted at American College of Cardiology, laughter ca...ef presenter of the paper Michael Miller, MD, dire...ssociate professor of medicine at the University o...ion after studying 300 participants, 150 healthy a...
Other Medicine News:
Pre-Loaded with a Stylet., ,Available Cuffed or Uncuffed, pre-loaded with a stylet to facilitate quick intubations.
Worlds 1st spray on medical gel lubricant, Sprayglyde was specifically designed to assist the insertion of laryngeal masks.
Pediatric Tracheal Tubes with Micro-thin-walled cuffs.
Indications For Usage: , Emergency use. , When medicant during ventilation is required.
Medicine Products: